COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
First Patient Randomized in Jaguar Health’s Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID)
Jaguar Health's crofelemer shows promise in reducing total parenteral support in pediatric MVID patient. Ongoing trials and future expectations discussed -
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research initiates coverage on Jaguar Health Inc, recommending a Buy with USD 60.00 price target. Jaguar focuses on plant-based medicines for GI health challenges, with crofelemer as flagship product -
-
-
